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Oxysterols activating liver X receptors (LXRs) repress expression of pro-inﬂammatory genes and
have anti-inﬂammatory effects. Here, we show for the ﬁrst time that bone marrow-derived murine
mast cells (BMMCs) predominantly express LXRb. 25-hydroxycholesterol, a representative LXR acti-
vating oxysterol, suppressed IL-6 production and degranulation response in BMMCs following
engagement of high-afﬁnity IgE receptor (FceRI). Interestingly, 25-hydroxycholesterol reduced
cell-surface FceRI expression by inhibiting assembly of FceRIa and FceRIb. We demonstrate that
LXR activation was involved in the suppression of IL-6 production in BMMCs, but that reduced FceRI
expression and degranulation response was mediated in an LXR-independent manner.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Mast cells express the high-afﬁnity IgE receptor (FceRI) on the
cell surface which plays crucial roles in the development of allergic
inﬂammation [1]. FceRI is mainly expressed on mast cells and
basophils as a tetramer comprised of an IgE-binding a-chain, two
types of signaling subunits, a b-chain, and a disulﬁde-linked
homodimer of c-chains [2]. The IgE-bound FceRI is engaged by
multivalent antigens for mast cell activation, and triggers the re-
lease of preformed intragranullar chemical mediators, synthesis
of eicosanoids, and the production of pro-inﬂammatory cytokines.
Liver X receptors (LXR)a and b are known as representative nu-
clear receptors and were recently reported to negatively regulate
expression of pro-inﬂammatory genes by inducing trans-repres-
sion [3]. Some oxysterols were identiﬁed as natural ligands for
LXR [4], and have anti-allergic activity; e.g., topical application ofchemical Societies. Published by E
ast cells; FceRI, high-afﬁnity
OHC, 25-hydroxycholesterol;
24(S),25-epoxycholesterol;
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-ku, Tokyo 173-8610, Japan.
.LXR-activating oxysterols in mice reduces irritant and allergic
cutaneous inﬂammation [5]. More recently, Heine et al. reported
that activation of LXRs reduces IgE production from B cells stimu-
lated with anti-CD40 and IL-4 [6].
In the present study, we found that bone marrow-derived mur-
ine mast cells (BMMCs) predominantly express LXRb but not LXRa.
Thus, we further investigated employing BMMCs whether 25-
hydroxycholesterol (25-OHC), 22(R)-hydroxycholesterol (22(R)-
OHC), and 24(S),25-epoxycholesterol (24(S),25-EC), all of which
are LXR activating oxysterols, suppress FceRI-dependent mast cell
activation including production of a representative pro-inﬂamma-
tory cytokine, IL-6.
2. Materials and methods
2.1. Antibodies and other reagents
Mouse anti-FceRIb monoclonal antibody (mAb) (clone JRK; the
hybridoma was a kind gift from Dr. Juan Rivera, NIH, USA) was pre-
pared in our laboratory. Rabbit anti-FceRIc polyclonal antibody
(#06-727) was purchased from Upstate (Lake Placid, NY, USA).
Armenian hamster anti-mouse FceRIa mAb (MAR-1) conjugated
with or without FITC and armenian hamster IgG isotype control
(#16-4888) was purchased from eBioscience (San Diego, CA,
USA). Horseradish peroxidase (HRP) conjugated secondary
polyclonal antibodies to rabbit IgG, armenian hamster IgG, andlsevier B.V. All rights reserved.
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erly, MA, USA), Santa Cruz Biotechnology (Santa Cruz, CA, USA),
and GE Healthcare Bio-sciences (Little Chalfont, UK), respectively.
Anti-TNP IgE (IgE-3) and FITC-conjugated anti-mouse IgE (R35-
72) mAbs were purchased from BD Pharmingen (San Diego, CA,
USA). The anti-TNP IgE was labeled with Alexa488 (Molecular
Probes/Invitrogen, Tokyo, Japan) in our laboratory. LY295427 was
purchased from Calbiochem (San Diego, CA, USA). 25-hydroxycho-
lesterol (25-OHC) was purchased from Sigma (St. Louis, MO, USA).
22(R)-hydroxycholesterol (22(R)-OHC) and T0901317 were pur-
chased from Cayman (Ann Arbor, Michigan, USA), and 24(S),25-
epoxycholesterol was purchased from Biomol (Plymouth Meeting,
PA, USA). 22(S)-hydroxycholesterol (22(S)-OHC) was purchased
from Steraloids (Newport, RI, USA).
2.2. Preparation of BMMCs
Following approval by the committee of animal care and use in
Nihon University, BMMCs were prepared from the femurs of 4- to
6-week-old C57BL/6J mice as previously described [7]. BMMCs
were used for experiments after 4–5 weeks of culture.
2.3. Treatment of BMMCs with oxysterols
BMMCs (5  105/ml) were incubated in culture medium con-
taining oxysterols (1, 5, or 10 lM) for 48 h.
2.4. Degranulation assay
The degranulation response was evaluated by b-hexosamini-
dase release as previously described [7]. Brieﬂy, IgE-sensitized
BMMCs (1  106/ml) were stimulated with or without 1 ng/ml
TNP-BSA (LSL, Tokyo, Japan) at 37 C for 30 min. Whole cell lysates
with 0.5% TritonX-100 were used to quantify the total b-hexosa-
minidase activity. The supernatant or the whole cell lysates wereA
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Fig. 1. 25-OHC reduces IL-6 production and degranulation response in mast cells upon Fc
b mRNA in BMMCs. Mouse liver was used as a positive control. Data shown are the mea
were treated with or without oxysterols for 48 h and then stimulated with IgE and anti
hexosaminidase net release. In (B) and (C), data shown are the mean ± S.D. of triplicates.
was performed to analyze differences between the cells treated with vehicle and the otincubated with p-nitrophenyl-2-acetamido-2-deoxy-b-D-glucopy-
ranoside 3.8 lM for 40 min at 37 C. The reaction was stopped by
the addition of glycine 0.2 M (pH 11.0), and then the absorbance
was measured at 415 nm wave length. The percentage of net b-
hexosaminidase release was calculated as follows: (supernatant
optical density of the stimulated cells  supernatant optical den-
sity of the unstimulated cells)/(total cell lysate optical density of
unstimulated cells  supernatant optical density value of unstim-
ulated cells)  100.
2.5. Measurement of IL-6
IgE-sensitized BMMCs (1  106/ml) were stimulated with or
without 1 ng/ml TNP-BSA for 6 h. The production of IL-6 was ana-
lyzed with a speciﬁc ELISA kit (Biosource International, Camarillo,
CA, USA)
2.6. Flow cytometry
Binding of IgE to FceRI was evaluated by employing IgE-
Alexa488. Brieﬂy, BMMCs (2  105) were incubated with 0.1 lg/
ml of IgE-Alexa488 at 4 C for 30 min. To evaluate FceRI expression
at the cell surface, BMMCs (2  105) were labeled with 0.1 lg/ml of
IgE at 4 C for 30 min. The cells were stained at 4 C for 30 min with
0.1 lg/ml anti-IgE mAb conjugated with FITC Alternatively,
BMMCs (2  105) were directly labeled with 0.1 lg/ml FITC-conju-
gated anti-mouse FceRIa mAb, or with isotype control mAb at 4 C
for 30 min. These cells were analyzed using a FACSCalibur (Becton
Dickinson Biosciences, San Jose, CA, USA).
2.7. Quantitative real-time PCR
cDNA was reverse transcribed from 1 lg of total RNA. For quan-
titative real time PCR, cDNAs was analyzed in the ABI PRISM 7000
sequence detection system using Power SYBR Green PCR Master5 μM 10 μM
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S. Nunomura et al. / FEBS Letters 584 (2010) 1143–1148 1145Mix (Applied Biosystems, Foster City, CA, USA). Primer sequences
for glyceraldehyde-3-phosphate dehydrogenase (GAPDH), LXRa,
LXRb, ABCA1, and LDL receptor (LDLR) were described as follows:
50-TGCACCACCAACTGCTTAG-30 and 50-GATGCAGGGATGATGTTC-
30 (GAPDH); 50-AGGAGTGTCGACTTCGAAA-30 and 50-TGTTCCTCT-
TCTTGCCGCTT-30 (LXRa); 50-AACATCTTCTCAGCCGATCG-30 and
50-TTCATGAGCATGCGTGGGAA-30 (LXRb); 50-ATTGCCAGACGGAGC-
CG-30 and 50-TGCCAAAGGGTGGCACA-30 (ABCA1); 50-AGAGGACG-
AGCTCCACATTT-30 and 50-TCATGCCACATCGTCCTCCA-30 (LDLR).
The ampliﬁed RNA values were normalized to the level of GAPDH
mRNA.
2.8. Immunoprecipitation and immunoblotting
Immunoprecipitation and immunoblotting were performed as
previously described [8]. Brieﬂy, cells (1  107) were lysed for
30 min on ice in lysis buffer (Tris–buffered saline containing
0.25% Triton-X100, 2 mM PMSF, 10 lg/ml aprotinin, 2 lg/ml leu-
peptin and pepstatin A, 50 mM NaF and 1 mM sodium orthovana-
date). The lysates were centrifuged for 15 min at 15 000g, and the
supernatant was collected. Anti-mouse FceRIa mAb (10 lg) and
isotype control (10 lg) was added to the supernatant and incu-
bated for 3 h at 4C. The immunecomplex was precipitated with
10 lg of protein-G-sepharose and then resuspended in an equal
volume of 2 sample buffer without reducing agent. The samples
were then boiled for 5 min at 100 C, separated by 10–20% gradient
SDS–PAGE, then transferred to an Immobilon-P membrane
(Millipore, Bedford, MA). The membrane was incubated with the
primary antibody and an appropriate secondary horseradish
peroxidase-conjugated antibody. Signals were detected usingA B
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Fig. 2. LXR activation is involved in suppression of FceRI-mediated IL-6 production. BMM
real-time PCR analyzes for expression of ABCA1 and LDLR mRNA. (B) IL-6 net production.
with ﬂow cytometry, using mouse IgE and anti-mouse IgE mAb FITC. Data shown are th
from three independent experiments. In (A) and (D), data shown are the mean ± S.D
performed to compare cells treated with vehicle to the other cells.enhanced chemiluminescence (GE Healthcare Bio-sciences). The
immunoreactive bands were scanned to produce digital images
that were quantiﬁed with SCION Image software.
2.9. Statistical analysis
The data shown are the means ± S.D. of at least triplicate sam-
ples. Statistical analysis was performed using Student’s t-test.
Probability values of less than 0.05 were considered as statistically
signiﬁcant.
3. Results
3.1. Treatment of mast cells with 25-OHC reduces IL-6 production and
degranulation response upon FceRI engagement
In preliminary experiments, we observed that BMMCs express
both LXRa and b constitutively (data not shown). Analyzes
employing quantitative real-time PCR show that the level of LXRb
expression was much higher than that of LXRa expression
(Fig. 1A). Next, we examined the effects of three oxysterols on
FceRI-dependent IL-6 production and degranulation response of
mast cells. BMMCs were cultured in the presence of 5 or 10 lM
oxysterols for 48 h. Cholesterol was used as a control. Under the
experimental conditions, cell viability was unaltered (data not
shown). As shown in Fig. 1B, all oxysterols, particularly 25-OHC,
signiﬁcantly suppressed IL-6 production. On the other hand, 25-
OHC and other oxysterols considerably or slightly suppressed the
degranulation response, respectively (Fig. 1C). Spontaneous release
from unstimulated cells was below 3% of the total content of theFcεRI expression
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Fig. 3. An LXR antagonist does not reverse suppression of FceRI expression and degranulation response. BMMCs (5  105/ml) were treated with 5 lM 25-OHC for 48 h in the
presence or absence of 22(S)-OHC. (A) Cell-surface expression of FceRI was analyzed with ﬂow cytometry, using mouse IgE and anti-mouse IgE mAb FITC. Data shown are the
mean ± S.D. of samples obtained from three separate experiments. (B) b-hexosaminidase net release. Data shown are the mean ± S.D. of triplicates. Similar results were
obtained from three independent experiments. In (A) and (B), Student’s t-test was performed to compare cells treated with 5 lM 25-OHC to the other cells.
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Fig. 4. 25-OHC decreases assembly of FceRIa and FceRIbc in mast cells. BMMCs (5  105/ml) were treated with 25-OHC at the indicated concentrations for 48 h. (A) Effects of
25-OHC on IgE-Alexa488 binding to FceRI. (B) Effects of 25-OHC on cell-surface FceRIa expression. (C) Cells (1  107/ml) were lysed in lysis buffer as described in Section 2.
Whole cell lysates were incubated with anti-FceRIa mAb (10 lg) or isotype control (10 lg). The immunoprecipitates were separated on 10–20% SDS–PAGE under non-
reducing condition, and then FceRIb or FceRIc co-precipitated with FceRIawas analyzed by immunoblotting with anti-FceRIamAb, anti-FceRIbmAb, or anti-FceRIc antibody.
Coomassie brilliant blue (CBB) staining of the anti-FceRIamAb showed comparable sample loading. In (A) and (B), data shown are the mean ± S.D. of samples obtained from
three independent experiments. In (C), the results shown are representative of three independent experiments with similar results.
1146 S. Nunomura et al. / FEBS Letters 584 (2010) 1143–1148whole cell lysates. Also, basal IL-6 secretion from unstimulated
cells was below threshold of the minimum detectable concentra-
tions (data not shown). These data indicate that LXR-activating
oxysterols, principally 25-OHC, act as potent inhibitors of FceRI-
dependent mast cell activation.
3.2. LXR activation is not responsible for suppression of the
degranulation response
To explore the participation of LXR activation in the suppression
of IL-6 production and the degranulation response, we examinedthe effects of a synthetic LXR agonist T0901317 on IL-6 production
and the degranulation response. Fig. 2A shows that 0.4 lM
T0901317 as well as 10 lM 25-OHC induced mRNA expression of
ABCA1, a LXR-target gene, in BMMCs. 10 lM 25-OHC reduced LDLR
mRNA expression but the synthetic LXR ligand did not reduce the
expression. As shown in Fig. 2B, treatment of BMMCs with 0.4 lM
T0901317 and 10 lM 25-OHC signiﬁcantly reduced FceRI-induced
IL-6 production. On the other hand, the same treatment with
T0901317 failed to reduce the degranulation response (Fig. 2C).
These results suggest that alternative machineries are involved in
25-OHC-mediated inhibition of the degranulation response. We
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Fig. 5. LY295427 restores decreased FceRI assembly and degranulation response in mast cells treated with 25-OHC. BMMCs (5  105/ml) were treated with 10 lM 25-OHC or
with 25-OHC plus 20 lM LY295427 for 48 h. (A) Quantitative real-time PCR analyzes for expression of LDLR mRNA. Data shown are the mean ± S.D. of samples obtained from
three independent experiments. (B) Effects of LY295427 on FceRI assembly. The immunoprecipitates were prepared from cells (1  107/ml) as in Fig. 4C. FceRIb co-
precipitated with FceRIawas analyzed by immunoblotting with anti-FceRIamAb or anti-FceRIbmAb. (C) Effects of LY295427 on cell-surface FceRIa expression. (D) Effects of
LY295427 on degranulation response. In (B) and (C), the results shown are representative of three independent experiments with similar results. In (D), data shown are the
mean ± S.D. of triplicates. Similar results were obtained from three independent experiments. In (A) and (D), Student’s t-test was performed between the cells treated with
vehicle and the other cells.
S. Nunomura et al. / FEBS Letters 584 (2010) 1143–1148 1147observed that 25-OHC, but not T0901317, considerably down-reg-
ulates expression of cell-surface FceRI (Fig. 2D).
3.3. 22(S)-OHC fails to antagonize 25-OHC-mediated inhibition of
FceRI expression and degranulation response
We employed 22(S)-OHC, a competitive LXR antagonist [9], to
clarify the participation of LXR activation in the 25-OHC-mediated
suppression of FceRI expression and the degranulation response.
Fig 3A and B show that the LXR antagonist did not reverse the sup-
pression of FceRI expression and degranulation response in mast
cells treated with 25-OHC.
3.4. 25-OHC decreases assembly of FceRIa and FceRIbc in mast cells
Because cell-surface FceRI expression is a critical element in the
FceRI-dependent mast cell response [10], we examined the mech-
anism for down-regulation of FceRI by 25-OHC. As shown in
Fig. 4A, 25-OHC reduced binding of IgE-Alexa488 to the FceRI in
a concentration-dependent manner. Consistent with this observa-
tion, FceRIa expression on the cell surface was decreased in
BMMCs treated with 25-OHC (Fig. 4B). However, the expression
of FceRIa, b, and c were unaltered at both the mRNA and protein
levels (data not shown). Because the appropriate assembly of FceRI
components is indispensable for cell-surface FceRI expression [11],
we examined whether 25-OHC affects assembly of FceRI in
BMMCs. Biochemical analyzes using immunoprecipitation with
anti-FceRIa mAb show that the association between FceRIa andFceRIbc was signiﬁcantly decreased in BMMCs treated with
10 lM 25-OHC (Fig. 4C).
3.5. LY295427 reverses suppression of FceRI assembly and
degranulation response in mast cells treated with 25-OHC
Sterol regulatory element-binding proteins (SREBPs) regulate
the expression of LDLR at the level of transcription [12]. As demon-
strated in Fig. 2A, 25-OHC signiﬁcantly downregulated the expres-
sion of LDLR mRNA in BMMCs, suggesting that 25-OHC decreased
the efﬁcacy of SREBPs in mast cells. LY295427 restores the dysreg-
ulation of SREBPs at the endoplasmic reticulum (ER) induced by
25-OHC, resulting in up-regulation of SREBP target genes including
LDLR [13]. In addition, it was reported that FceRIa assembles with
FceRIb in the ER [14]. We therefore considered that LY295427 may
reverse the inhibitory actions of 25-OHC on FceRI expression and
the degranulation response in mast cells. Fig. 5A shows that
20 lM LY295427 restored the decrease in LDLR mRNA expression
in BMMCs treated with 10 lM 25-OHC. As shown in Fig. 5B and
C, decreases in cell-surface expression of FceRI as well as assembly
of FceRIa and FceRIb in 25-OHC loaded cells, were nearly reversed
by treatment with 20 lM LY29542. Furthermore, suppression of
the degranulation response was also restored (Fig. 5D).
4. Discussion
In the present study, we demonstrated that inhibitory actions of
25-OHC on FceRI-mediated mast cell activation occur via
1148 S. Nunomura et al. / FEBS Letters 584 (2010) 1143–1148LXR-dependent and -independent mechanisms. With regard to
LXR-dependent inhibition, we showed that LXR activation mainly
contributed to 25-OHC-mediated repression of IL-6 production.
However, we believe that the LXR-independent mechanism is also
involved in the reduction of IL-6 production observed in mast cells
treated with 25-OHC given that the inhibitory effect of the speciﬁc
LXR ligand T0901317 on IL-6 production was much less than that
of 25-OHC (Fig. 2B). In macrophages, trans-repression through nu-
clear receptor co-repressor is responsible for LXR-mediated repres-
sion of pro-inﬂammatory gene expression in response to
lipopolysaccharide [3], but it is unclear whether the same mecha-
nism is responsible for LXR-mediated repression of the FceRI-med-
iated IL-6 production in mast cells. Therefore, we are currently
investigating the underlying mechanism of this trans-repression
in mast cells.
Figs. 2D and 3A collectively indicate that one of the LXR-inde-
pendent effects of 25-OHC on mast cells is down-regulation of
FceRI at the cell surface. Murine FceRIa does not assemble with
FceRIc in the absence of FceRIb [15]; we thus concluded that de-
creased cell-surface FceRI expression is principally due to reduc-
tion of the association between FceRIa and FceRIb. LY295427
nearly reversed the effects of 25-OHC on assembly between FceRIa
and FceRIb (Fig. 4B). We could not elucidate how SREBPs maintain
FceRI assembly in BMMCs. Because biological functions of SREBPs
are affected by ER stress including the accumulation of unfolded
proteins [16–18], we believe that SREBPs might participate in ER
quality control, which is indispensable for the appropriate assem-
bly of FceRI.
As compared to 25-OHC, 22(R)-OHC showed slight suppressive
effects on IL-6 production and degranulation response of mast cells
although they are structurally very similar. A part of the differ-
ences may be explained by a previous report, which demonstrated
25-OHC is stronger repressor for function of SREBPs than 22(R)-
OHC [19]. Alternatively, different LXR ligand-complex formations
might lead to different biological actions including selective mod-
ulation. In tissues or cells, 25-OHC is synthesized from cholesterol
by cholesterol 25-hydroxylase [20]. In general, however, low levels
(several nM) of 25-OHC are present in human plasma [21]. There-
fore, administration of 25-OHC may be one of practical approaches
for the treatment of allergic inﬂammation. In addition, a previous
study reported that T0901317 attenuates IgE synthesis by human
and murine B cells at 108 M. On the other hand, T0901317 re-
duced FceRI-dependent cytokine production from BMMCs at
106 M. Since IgE production is maximally inhibited in B cells trea-
ted with 106 M T0901317, at the concentration of the LXR agonist,
it might exhibit synergistic anti-allergic effects.
In conclusion, we addressed novel actions of oxysterols on
FceRI-dependent mast cell activation, and our ﬁndings in the pres-
ent study provide useful information for future therapeutic strate-
gies for the prevention of allergic inﬂammation.
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